Ms. Brege is Managing Director of Cervantes Life Science Partners, LLC., a healthcare advisory and consulting company. Prior to joining Cervantes Life Science Partners from September 2012 to July 2015, Ms. Brege served as Chief Executive Officer and President of Nodality, Inc., a privately held biotechnology company focused on oncology and immunology.
Previously, Ms. Brege held several senior-level positions at Onyx Pharmaceuticals, Inc. from June 2006 to December 2011, including Executive Vice President and Chief Operating Officer. Before joining Onyx, Ms. Brege was a general partner at Red Rock Capital Management, a venture capital firm specializing in early stage financing for technology companies. Prior to Red Rock, she was Senior Vice President and Chief Financial Officer at COR Therapeutics. Earlier in her career, Ms. Brege served as Vice President and Chief Financial Officer at Flextronics and Vice President and Treasurer of The Cooper Companies.
Ms. Brege serves on the boards of Dynavax Technologies Corporation, HLS Therapeutics Inc., Pacira BioSciences, Inc., and Portola Pharmaceuticals, Inc. Ms. Brege earned her undergraduate degree from Ohio University and has an M.B.A. from the University of Chicago.
What is Laura Brege's net worth?
The estimated net worth of Laura Brege is at least $225,618.42 as of June 12th, 2023. Ms. Brege owns 13,502 shares of ACADIA Pharmaceuticals stock worth more than $225,618 as of April 26th. This net worth estimate does not reflect any other investments that Ms. Brege may own. Learn More about Laura Brege's net worth.
How do I contact Laura Brege?
Has Laura Brege been buying or selling shares of ACADIA Pharmaceuticals?
Laura Brege has not been actively trading shares of ACADIA Pharmaceuticals during the last ninety days. Most recently, Laura Brege sold 4,500 shares of the business's stock in a transaction on Monday, June 12th. The shares were sold at an average price of $24.87, for a transaction totalling $111,915.00. Following the completion of the sale, the director now directly owns 13,502 shares of the company's stock, valued at $335,794.74. Learn More on Laura Brege's trading history.
Who are ACADIA Pharmaceuticals' active insiders?
Are insiders buying or selling shares of ACADIA Pharmaceuticals?
During the last year, ACADIA Pharmaceuticals insiders bought shares 1 times. They purchased a total of 209,053 shares worth more than $5,312,036.73. During the last year, insiders at the biopharmaceutical company sold shares 33 times. They sold a total of 337,790 shares worth more than $8,216,006.23. The most recent insider tranaction occured on April, 8th when CEO Stephen Davis sold 26,574 shares worth more than $474,877.38. Insiders at ACADIA Pharmaceuticals own 27.5% of the company.
Learn More about insider trades at ACADIA Pharmaceuticals. Information on this page was last updated on 4/8/2024.
